These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
252 related items for PubMed ID: 31293091
1. Hürthle cell lesions on thyroid fine needle aspiration cytology: Molecular and histologic correlation. Schatz-Siemers N, Brandler TC, Oweity T, Sun W, Hernandez A, Levine P. Diagn Cytopathol; 2019 Oct; 47(10):977-985. PubMed ID: 31293091 [Abstract] [Full Text] [Related]
3. The prevalence and surgical outcomes of Hürthle cell lesions in FNAs of the thyroid: A multi-institutional study in 6 Asian countries. Agarwal S, Bychkov A, Jung CK, Hirokawa M, Lai CR, Hong S, Kwon HJ, Rangdaeng S, Liu Z, Su P, Kakudo K, Jain D. Cancer Cytopathol; 2019 Mar; 127(3):181-191. PubMed ID: 30668897 [Abstract] [Full Text] [Related]
4. ThyroSeq v3 for Bethesda III and IV: An institutional experience. Desai D, Lepe M, Baloch ZW, Mandel SJ. Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808 [Abstract] [Full Text] [Related]
5. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration? Pu RT, Yang J, Wasserman PG, Bhuiya T, Griffith KA, Michael CW. Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553 [Abstract] [Full Text] [Related]
6. Molecular alterations in Hürthle cell neoplasms of thyroid: A fine needle aspiration cytology study with cytology-histology correlation. Gilani SM, Ross JA, Prasad ML, Hammers L, Cai G, Adeniran AJ. Cancer Cytopathol; 2021 May; 129(5):363-373. PubMed ID: 33045146 [Abstract] [Full Text] [Related]
9. The Presence of Hürthle Cells Does Not Increase the Risk of Malignancy in Most Bethesda Categories in Thyroid Fine-Needle Aspirates. Ren Y, Kyriazidis N, Faquin WC, Soylu S, Kamani D, Saade R, Torchia N, Lubitz C, Davies L, Stathatos N, Stephen AE, Randolph GW. Thyroid; 2020 Mar; 30(3):425-431. PubMed ID: 32013786 [Abstract] [Full Text] [Related]
10. Hurthle cells in fine needle aspiration cytology of the thyroid: a potential diagnostic dilemma? Wong YP, Md Isa N, Md Zin RR, Noor Akmal S. Malays J Pathol; 2015 Apr; 37(1):49-52. PubMed ID: 25890614 [Abstract] [Full Text] [Related]
15. A case series of thyroid fine needle aspiration biopsies diagnosed as follicular neoplasm with oncocytic features. Chen CV, Krishnan V, Greenland NY. Diagn Cytopathol; 2024 Oct; 52(10):553-557. PubMed ID: 38581413 [Abstract] [Full Text] [Related]
16. Hurthle cell predominance impacts results of Afirma gene expression classifier and ThyroSeq molecular panel performance in indeterminate thyroid nodules. Parajuli S, Jug R, Ahmadi S, Jiang XS. Diagn Cytopathol; 2019 Nov; 47(11):1177-1183. PubMed ID: 31348619 [Abstract] [Full Text] [Related]
18. Benign call rate and molecular test result distribution of ThyroSeq v3. Ohori NP, Landau MS, Carty SE, Yip L, LeBeau SO, Manroa P, Seethala RR, Schoedel KE, Nikiforova MN, Nikiforov YE. Cancer Cytopathol; 2019 Mar; 127(3):161-168. PubMed ID: 30561907 [Abstract] [Full Text] [Related]
19. Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: A cytomorphologic study of 139 cases with statistical analysis. Elliott DD, Pitman MB, Bloom L, Faquin WC. Cancer; 2006 Apr 25; 108(2):102-9. PubMed ID: 16453320 [Abstract] [Full Text] [Related]